Sanofi's fight for a better research reputation

France's largest drug company is in the middle of a transformation. Late last year, shortly after bringing on a new CEO, Sanofi announced plans to exit the heart and diabetes research that had long been its calling card. In its place, the company put greater emphasis on developing drugs for cancer, immune diseases and uncommon blood disorders.